Related Experiment Videos
[Has interleukin 2 modified the outcome of metastatic kidney cancer?]
Annales D'Urologie
|January 1, 1993
Abstract:
Immunotherapy offers a limited but definite hope in the course of metastatic renal cancer. Interferon alpha gives 2% complete remissions and 14% partial responses. Interleukin 2 achieves 5-10% complete remissions and 20% partial responses. The combination of the two agents does not really improve the results. In contrast, culture of TIL cells in the presence of IL-2 provides encouraging results.
Insights
Immunotherapy for metastatic renal cancer shows promise. While Interferon alpha and Interleukin 2 offer some benefits, combining them doesn't improve outcomes. Culturing tumor-infiltrating lymphocytes (TIL) with IL-2 yields encouraging results.
Area of Science:
- Oncology
- Immunology
Background:
- Metastatic renal cancer (kidney cancer) has limited treatment options.
- Immunotherapy is an emerging treatment modality for advanced cancers.
Purpose of the Study:
- To evaluate the efficacy of different immunotherapy approaches for metastatic renal cancer.
- To compare Interferon alpha, Interleukin 2, their combination, and TIL cell therapy.
Main Methods:
- Review of existing data on Interferon alpha and Interleukin 2 efficacy.
- Analysis of treatment outcomes for combined Interferon alpha and Interleukin 2.
- Assessment of results from tumor-infiltrating lymphocyte (TIL) cell therapy cultured with IL-2.
Main Results:
- Interferon alpha: 2% complete remissions, 14% partial responses.
- Interleukin 2: 5-10% complete remissions, 20% partial responses.
- Combination therapy did not significantly improve response rates compared to single agents. TIL cell therapy with IL-2 showed promising results.
Conclusions:
- Standard immunotherapy agents like Interferon alpha and Interleukin 2 provide limited benefit in metastatic renal cancer.
- Combining Interferon alpha and Interleukin 2 does not enhance efficacy.
- Tumor-infiltrating lymphocyte (TIL) therapy, when cultured with Interleukin 2, represents a more promising immunotherapy strategy for this condition.